Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$2.51 USD
+0.19 (8.19%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $2.51 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Adverum Biotechnologies, Inc.'s return on equity, or ROE, is -130.53% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.55%. While this shows that ADVM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ADVM 2.51 +0.19(8.19%)
Will ADVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Bet on 5 Top-Ranked Stocks With Rising P/E
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Other News for ADVM
Adverum Biotechnologies (ADVM) Price Target Reduced by Mizuho | ADVM Stock News
Adverum Biotechnologies (ADVM) Price Target Reduced by Mizuho | ADVM Stock News
Adverum Biotechnologies price target lowered to $12 from $16 at Mizuho
Adverum Biotechnologies price target lowered by $4 at Mizuho, here's why
Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)